- Home
- MXCT vs APLT Comparison
MXCT vs APLT Comparison
Compare MXCT & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MXCT
- APLT
- Stock Information
- Founded
- MXCT 1999
- APLT 2016
- Country
- MXCT United States
- APLT United States
- Employees
- MXCT N/A
- APLT N/A
- Industry
- MXCT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- MXCT Health Care
- APLT Health Care
- Exchange
- MXCT Nasdaq
- APLT Nasdaq
- Market Cap
- MXCT 159.9M
- APLT 178.6M
- IPO Year
- MXCT 2021
- APLT 2019
- Fundamental
- Price
- MXCT $1.67
- APLT $0.89
- Analyst Decision
- MXCT Buy
- APLT Buy
- Analyst Count
- MXCT 4
- APLT 5
- Target Price
- MXCT $7.50
- APLT $4.13
- AVG Volume (30 Days)
- MXCT 561.6K
- APLT 2.6M
- Earning Date
- MXCT 11-12-2025
- APLT 11-10-2025
- Dividend Yield
- MXCT N/A
- APLT N/A
- EPS Growth
- MXCT N/A
- APLT N/A
- EPS
- MXCT N/A
- APLT N/A
- Revenue
- MXCT $35,754,000.00
- APLT $121,000.00
- Revenue This Year
- MXCT N/A
- APLT N/A
- Revenue Next Year
- MXCT $14.72
- APLT $5,935.35
- P/E Ratio
- MXCT N/A
- APLT N/A
- Revenue Growth
- MXCT N/A
- APLT N/A
- 52 Week Low
- MXCT $1.26
- APLT $0.30
- 52 Week High
- MXCT $5.20
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- MXCT 54.49
- APLT 40.23
- Support Level
- MXCT $1.45
- APLT $1.08
- Resistance Level
- MXCT $1.57
- APLT $1.24
- Average True Range (ATR)
- MXCT 0.11
- APLT 0.14
- MACD
- MXCT -0.00
- APLT -0.07
- Stochastic Oscillator
- MXCT 71.40
- APLT 0.00
About MXCT MaxCyte Inc.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.